Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc

Bullboard Posts

Post by JLGeminion Mar 14, 2011 1:15pm

280 Views

Post# 18281864

Buying Opportunity - Oncolytics on Sale Today

Some institutional traders opened the market today with large sell orders: 45,000 shares on the NASDAQ and 18,000 on the TSX. Their objective was to spread fear to cause retail investors to panic and sell their shares. It did not happen. All that they accomplished was to set the daily lows of $5.70 and $5.26. Retail investors hold onto your shares the April 2009 story of Dendreon, DNDN on the Nasdaq, is going to be repeated with Oncolytics soon. Consider buying and using margin. Institutional investors are wise to recognize the risk of condoning the buy side manipulation and acquire their position quickly. Time is not your friend and you may not have enough time to buy. There will be more competition for shares as short sellers will need to cover their positions.

Here is table showing the trading of Dendreon in April 2009.

Date	Closing Price	Volume
1-Apr-09	$4.14	3,199,650
2-Apr-09	4.34	2,427,867
3-Apr-09	5.99	22,497,200
6-Apr-09	6.58	19,585,750
7-Apr-09	6.58	7,346,062
8-Apr-09	6.37	5,392,639
9-Apr-09	6.30	4,234,697
13-Apr-09	7.30	12,775,310
14-Apr-09	16.99	65,120,890
15-Apr-09	17.17	19,294,060
16-Apr-09	17.03	6,894,881
17-Apr-09	17.99	17,799,470
20-Apr-09	19.52	17,724,250
21-Apr-09	19.74	11,008,510
22-Apr-09	20.12	7,358,435
23-Apr-09	20.33	6,123,418
24-Apr-09	20.08	7,393,327
27-Apr-09	21.55	18,569,850
28-Apr-09	11.81	28,070,740
29-Apr-09	22.94	48,235,790
30-Apr-09	21.20	17,468,950
Friday Close
11-Mar-11	$33.80	2,036,250